

August 1, 2024

OTC Markets Group Inc.  
304 Hudson Street, Third Floor  
New York, NY 10013111 Broadway  
Suite 807  
New York, NY 10006T – (212) 417-8160  
F – (212) 417-8161

---

[www.lucbro.com](http://www.lucbro.com)**Re: Attorney Letter with Respect to Adequate Current  
Information of Creatd, Inc. (“OTCQB: CRTD”)**

Dear Sir or Madam:

We have been engaged by Creatd, Inc., a Nevada corporation (the “Company”) to review the Company’s annual and quarterly reports referenced below that have been filed with the OTC Markets Group Inc. (the “OTC Markets Group”) and that are published in the OTC Disclosure & News Service as of the date hereof (the “Reports”); and to render this opinion letter in accordance with the OTC Markets Group’s Attorney Letter Agreement and the accompanying Attorney Letter Guidelines as to whether the Reports regarding the Company and its shares of common stock, par value \$0.001 per share (the “Common Stock”) that are publicly traded on the OTC Markets Group’s “OTCQB Market” under the trading symbol “CRTD” (the “Company Securities”): (i) constitutes “adequate current public information” concerning the Company and the Company Securities and “is available” within the meaning of Rule 144(c)(2) promulgated by the United States Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities Act”); (ii) includes all of the Reports that a broker-dealer would be required to obtain from the Company to publish a quotation of the Company Securities under Rule 15c2-11 promulgated by the SEC under the Securities Exchange Act of 1934, as amended (the “Exchange Act”); (iii) complies with the OTC Markets Group’s “OTCPink Basic Disclosure Guidelines” published on the Internet at [www.otcmarkets.com](http://www.otcmarkets.com); and (iv) has been posted through the OTC Disclosure & News Service, among other matters

I, Scott E. Linsky, the author and signatory of this legal opinion, am a Partner at Lucosky Brookman LLP. I am a U.S. resident and licensed to practice law in the states of New York and New Jersey. I am permitted to practice before the SEC and have not, at any time, been prohibited from practice thereunder. The jurisdictions covered by this letter include the laws of the United States of America. This letter does not rely on the work of other counsel. I have not currently, nor have been in the past five years, suspended or barred from practicing in any state or jurisdiction, nor charged in a civil or criminal case. I am not currently, nor have I been in the past five years, been the subject of an investigation, hearing, or proceeding by the SEC, the U.S. Commodity Futures Trading Commission (CFTC), the Financial Industry Regulatory Authority (FINRA), or any other federal, state, or regulatory agency. I have examined such corporate records and other documents and such questions of law that I have considered necessary or appropriate for the

purposes of rendering this letter. The documents that I have reviewed include, but are not limited to:

- the Company's Annual Report for the fiscal year ended December 31, 2023, published to the OTC Markets Group on June 28, 2024;
- the Company's Quarterly Report for the period ended March 31, 2024, published to the OTC Markets Group on July 12, 2024; and
- the Company's Quarterly Report for the period ended June 30, 2024, published to the OTC Markets Group on July 31, 2024.

As to matters of fact, I have relied on information obtained from public officials, officers and directors of the Company and other sources, and these sources are believed to be reliable. In examining the Reports, I have assumed that: (a) all statements and representations contained therein were accurate and reliable; (b) all signatures contained therein were genuine; (c) all documents submitted to me were true and accurate copies; and (d) all natural persons who signed documents had the legal capacity to do so.

Based on my review and other matters set forth herein, it is my opinion that the Reports (i) constitute "adequate current public information" concerning the Securities and the Company; (ii) have been made publicly available within the meaning of Rule 144(c)(2) under the Securities Act; (iii) include all of the information that a broker-dealer would be required to obtain from the Company to publish a quotation for the Securities under Rule 15c2-11 under the Exchange Act; (iv) comply as to form with the OTC Markets Group's OTC Pink Basic Disclosure Guidelines; and (v) have been posted through the OTC Disclosure & News Service.

The Company's management is responsible for the preparation of the corporate filings. The Company's unaudited financial statements for the fiscal year ended December 31, 2023 included in the Company's Annual Report, and for the periods ended March 31, 2024 and June 30, 2024 included in the Company's Quarterly Reports for such periods, were prepared by Jeremy Frommer, Chief Executive Officer, and Chelsea Pullano, Head of Filings and Compliance.

The Company's transfer agent is Pacific Stock Transfer Company, with an address of 6725 Via Austi Pkwy, Suite 300, Las Vegas, Nevada 89119 (the "Transfer Agent"). The Transfer Agent is registered with the SEC. We have confirmed with the Company and Transfer Agent that as of December 31, 2023, the issued and outstanding capital stock of the Company consisted of 253,981,148 shares of common stock, par value \$0.001 per share, issued and outstanding. For the aforesaid confirmation, we relied on the certified shareholders' list of the Company dated as of December 31, 2023, and prepared and provided to us by the Transfer Agent. The Company effected a 1-for-500 reverse stock split on January 24, 2024. The Company has determined that, giving effect to such reverse stock split and certain related required adjustments, the number of shares deemed issued and outstanding as of December 31, 2023 is 507,201. The number of shares issued and outstanding as of June 30, 2024 is 2,795,778.

I have (i) met with the management of the Company, Jeremy Frommer and Chelsea Pullano, through video conference call, (ii) reviewed the Information, as amended, published by the Company through the OTC Disclosure and News Service and (iii) discussed the information with management and its director

To the best of my knowledge, after reasonable inquiry of management and the board of directors of the Company, neither the Company, nor any 5% holders of securities of the Company, nor any members of my firm are currently under investigation by any federal or state securities laws.

The Company is currently not a “shell company” as defined in Rules 405 of the Securities Act and 12b- 2 of the Exchange Act; however, the Company may be deemed to have previously been a “shell company.”

This letter confirms that as of the date of this opinion, Lucosky Brookman LLP does not own any shares of common stock of the Company (the “Shares”). We do not have any agreement to receive in the future any shares of the Company’s stock, whether in payment for services or otherwise; however, we may receive such shares in the future for payment of services as outside securities counsel to the Company.

The opinions expressed herein are solely for the benefit of the OTC Markets Group, which is entitled to rely on this letter in determining whether the Company has made adequate information publicly available within the meaning of Rule 144(c)(2) under the Securities Act, and may not be relied on in any manner or for any purpose by any other person or entity and may not be quoted in whole or in part without my prior written consent. We hereby grant the OTC Markets Group full and complete permission and rights to publish this letter through the OTC Disclosure and News Service for viewing by the public and regulators.

The opinions expressed herein are given as of the date hereof, and we undertake no obligation to supplement this letter if any applicable laws change after the date hereof or if we become aware of any facts that might change the opinions expressed herein after the date hereof for any reason.

Very Truly Yours,  
Lucosky Brookman LLP

*/s/ Scott E. Linsky*